ALXN2030
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 23, 2025
CONCORD: Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
(clinicaltrials.gov)
- P2 | N=45 | Active, not recruiting | Sponsor: Alexion Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Antibody-mediated Rejection • Transplantation
April 16, 2025
Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Alexion Pharmaceuticals, Inc. | Trial primary completion date: Feb 2025 ➔ Oct 2026 | Trial completion date: Feb 2025 ➔ Oct 2026
Trial completion date • Trial primary completion date
March 20, 2025
CONCORD: Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
(clinicaltrials.gov)
- P2 | N=45 | Recruiting | Sponsor: Alexion Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Antibody-mediated Rejection • Transplantation
December 20, 2024
CONCORD: Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
(clinicaltrials.gov)
- P2 | N=45 | Not yet recruiting | Sponsor: Alexion Pharmaceuticals, Inc.
New P2 trial • Antibody-mediated Rejection • Transplantation
1 to 4
Of
4
Go to page
1